Cite
APA Citation
Moura, F., Wiviott, S., Chertow, G., Dwyer, J., Gause-Nilsson, I., Johansson, P., Langkilde, A., McMurray, J., Mosenzon, O., Raz, I., Rossing, P., Wheeler, D., Sabatine, M., & Heerspink, H. (n.d.). effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. European heart journal, 43, . http://access.bl.uk/ark:/81055/vdc_100168329921.0x00002d